Fulgent Genetics Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Caribou Biosciences to halt CAR-T programs, explore sale
- Sportradar to sell Synergy Sports coaching unit for $170M
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Fulgent Genetics, Inc. (FLGT) Tops Q2 EPS by 5c
August 4, 2022 5:08 PM EDTFulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of $0.78, $0.05 better than the analyst estimate of $0.73. Revenue for the quarter came in at $125.3 million versus the consensus estimate of $122.7 million.
GUIDANCE:
Fulgent Genetics, Inc. sees Q3 2022 revenue of $105 million, versus the... More



